LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Assessment of Miniature AsCas12f1 Variants for Gene Editing and Activation

Miniature CRISPR/Cas systems possess delivery advantages for gene therapy. The type V‐F Cas12f1 from Acidibacillus sulfuroxidans is exceptionally compact (422 amino acids) and has been engineered by several studies as… Click to show full abstract

Miniature CRISPR/Cas systems possess delivery advantages for gene therapy. The type V‐F Cas12f1 from Acidibacillus sulfuroxidans is exceptionally compact (422 amino acids) and has been engineered by several studies as compact genome editing tools through protein and single guide RNA (sgRNA) engineering. However, a comparative evaluation of gene editing and activation efficiencies mediated by different AsCas12f1 variants and sgRNA scaffolds is lacking. This study tested combinations of four AsCas12f1 protein variants and six sgRNA scaffolds for their gene editing and transcription activation efficiencies. The protein variant AsCas12f1‐HKRA performed the best in gene editing and activation when paired with sgRNA‐en_v2.1 scaffold. Furthermore, we validated a super miniature gene activator by fusing a small activation domain to AsCas12f1‐HKRA. Our findings recommend using AsCas12f1‐HKRA and sgRNA‐en_v2.1 for gene editing and activation applications.

Keywords: gene editing; activation; ascas12f1; miniature; gene; editing activation

Journal Title: Biotechnology and Bioengineering
Year Published: 2025

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.